Trial · NCT00950690
Efficacy and Tolerability of Xalatan in Patients
NCT00950690, Completed, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; results first posted 2009-08-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Tolerability of Xalatan in Patients. Trials, record NCT00950690. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00950690
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Tolerability of Xalatan in Patients
- NCT number
- NCT00950690
- Status
- Completed
- Enrollment
- 1,289 participants, actual
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Xalatan 0.005% eye drops
- First posted
- 2009-08-03
- Last updated
- 2021-02-25
- Results first posted
- 2009-08-03
- Limitations and caveats
Efficacy data were not summarized or analyzed because data collection did not permit clear identification of IOP \& visual field data in this non-monitored observational study. Consequently, data were not sufficiently interpretable.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intraocular Pressure | Screening, 10 days, 4 weeks and 12 weeks after beginning treatment | Intraocular pressure was measured at each visit |
| Primary | Humphrey Perimetry Visual Field | Visits 1 and 4 | Analysis of visual field deficits for abnormalities. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Intraocular Pressure | Screening, 10 days, 4 weeks and 12 weeks after beginning treatment | Data collection process did not permit clear identification of IOP \& visual field data in non-monitored study. Efficacy data not sufficiently interpretable for statistical summaries. | ||
| PRIMARY | Humphrey Perimetry Visual Field | Visits 1 and 4 | Data collection process did not permit clear identification of IOP \& visual field data in non-monitored study. Efficacy data not sufficiently interpretable for statistical summaries. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Xalatan | 1,349 | |
| Overall Study | COMPLETED | Xalatan | 1,105 | |
| Overall Study | NOT COMPLETED | Xalatan | 244 |
Source ClinicalTrials.gov
Adverse events36
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Palpitations | Cardiac disorders | Xalatan | 1 | 1,349 | |
| other | Ear Pain | Ear and labyrinth disorders | Xalatan | 1 | 1,349 | |
| other | Conjunctival follicles | Eye disorders | Xalatan | 1 | 1,349 | |
| other | Conjunctival hyperaemia | Eye disorders | Xalatan | 7 | 1,349 | |
| other | Conjunctivitis | Eye disorders | Xalatan | 2 | 1,349 | |
| other | Corneal erosion | Eye disorders | Xalatan | 2 | 1,349 | |
| other | Dry eye | Eye disorders | Xalatan | 4 | 1,349 | |
| other | Eye disorder | Eye disorders | Xalatan | 4 | 1,349 | |
| other | Eye irritation | Eye disorders | Xalatan | 1 | 1,349 | |
| other | Eye pain | Eye disorders | Xalatan | 1 | 1,349 |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Xalatan | ||
| Total, other adverse events | Xalatan | 101 | |
| Total, serious adverse events | Xalatan | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00950690
GET https://conductscience.org/api/trials/v1/NCT00950690/events?page=2